Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design

Maria Reig, Jordi Rimola, Ferran Torres, Anna Darnell, Carlos Rodriguez‐Lope, Alejandro Forner, Neus LLarch, José Ríos, Carmen Ayuso, Jordi Bruix – 20 June 2013 – Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. Thus, time to tumor progression (TTP) is used to capture benefits of novel molecular agents, but proof of its surrogacy with survival is lacking.

Growth and development of a new subspecialty: Pediatric hepatology

William F. Balistreri – 20 June 2013 – Several major forces converged to catalyze the formal emergence of a body of knowledge and an organized focus on disorders of the liver in early life. Attendant to the development of a focused clinical subspecialty the pace of patient‐ and laboratory‐based research in the field quickened in parallel to decipher the consequences of genetic or metabolic aberrations on immature liver structure and function.

Epigenetic silencing of DACH1 induces loss of transforming growth factor‐β1 antiproliferative response in human hepatocellular carcinoma

Hongbin Zhu, Kongming Wu, Wenji Yan, Ling Hu, Jing Yuan, Yan Dong, Yazhuo Li, Kunyu Jing, Yunsheng Yang, Mingzhou Guo – 20 June 2013 – Human dachshund homolog 1 (DACH1) is a major component of the Retinal Determination Gene Network (RDGN) and functions as a tumor suppressor. However, the regulation of DACH1 expression and its function in hepatocellular carcinoma (HCC) remain unclear. In this study, epigenetic changes of DACH1 were analyzed in HCC cell lines and primary cancers.

Subscribe to